Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.

Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ

The Journal of clinical endocrinology and metabolism18 Mar 2008Cited by 41 (Europe PMC)

PMID18349061PMCIDPMC2435646DOI10.1210/jc.2007-2781PepBankPUB-18349061

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with femoral neck BMD T-score between -1.0 and -2.0, PTH(1-84) increased lumbar spine areal BMD by 2.1% versus placebo at 12 months.
In plain wordsIn postmenopausal women, PTH increased spine bone density by 2.1% versus placebo at 12 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine areal BMD
Study
n = 50
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 mug daily for 1 month, then weekly for 11 months · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Lumbar spine areal BMD increase versus placebo
2.1%
12 months, PTH-treated versus placebo
Source sentences
Summary
At 12 months, lumbar spine areal BMD increased 2.1% in PTH-treated women compared with placebo (P = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Change in lumbar spine dual-energy x-ray absorptiometry areal BMD (primary) was assessed.
Summary · context
Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME.InterventionSubjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 mont…
Report a problemFND-1834906101
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, vertebral trabecular volumetric BMD increased 3.8% with PTH(1-84) versus placebo (P = 0.08).
In plain wordsIn postmenopausal women, vertebral volumetric bone density increased 3.8% with PTH versus placebo (P = 0.08).
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseVertebral trabecular volumetric BMD
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 mug daily for 1 month, then weekly for 11 months · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Vertebral trabecular volumetric BMD increase versus placebo
3.8%
12 months, PTH-treated versus placebo
Source sentences
Summary
Vertebral trabecular volumetric BMD increased 3.8% in PTH-treated women compared with placebo group (P = 0.08).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included volumetric BMD at spine and hip by quantitative computed tomography, trabecular bone microarchitecture by magnetic resonance imaging of distal radius, and biochemical bone turnover markers.
Summary · context
Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME.InterventionSubjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 mont…
Report a problemFND-1834906102
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, distal radial trabecular bone volume was higher with PTH(1-84) than placebo.
In plain wordsIn postmenopausal women, wrist trabecular bone volume was higher with PTH than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseDistal radial trabecular bone volume
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 mug daily for 1 month, then weekly for 11 months · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
PTH-treated women also had higher distal radial trabecular bone volume, number, and thickness compared with placebo-treated women (P < 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included volumetric BMD at spine and hip by quantitative computed tomography, trabecular bone microarchitecture by magnetic resonance imaging of distal radius, and biochemical bone turnover markers.
Summary · context
Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME.InterventionSubjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 mont…
Report a problemFND-1834906103
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, distal radial trabecular number was higher with PTH(1-84) than placebo.
In plain wordsIn postmenopausal women, wrist trabecular number was higher with PTH than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseDistal radial trabecular number
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 mug daily for 1 month, then weekly for 11 months · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
PTH-treated women also had higher distal radial trabecular bone volume, number, and thickness compared with placebo-treated women (P < 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included volumetric BMD at spine and hip by quantitative computed tomography, trabecular bone microarchitecture by magnetic resonance imaging of distal radius, and biochemical bone turnover markers.
Summary · context
Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME.InterventionSubjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 mont…
Report a problemFND-1834906104
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, distal radial trabecular thickness was higher with PTH(1-84) than placebo.
In plain wordsIn postmenopausal women, wrist trabecular thickness was higher with PTH than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseDistal radial trabecular thickness
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 mug daily for 1 month, then weekly for 11 months · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
PTH-treated women also had higher distal radial trabecular bone volume, number, and thickness compared with placebo-treated women (P < 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included volumetric BMD at spine and hip by quantitative computed tomography, trabecular bone microarchitecture by magnetic resonance imaging of distal radius, and biochemical bone turnover markers.
Summary · context
Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME.InterventionSubjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 mont…
Report a problemFND-1834906105
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, P1NP increased markedly after 1 month of daily PTH(1-84) versus placebo.
In plain wordsIn postmenopausal women, P1NP increased after 1 month of daily PTH versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseP1NP at 1 month
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 mug daily · subcutaneous · 1 monthAs given in this study (human).
Source sentences
Summary
After 1 month of daily PTH, N-terminal propeptide of type I collagen (P1NP) was markedly increased compared with placebo (P < 0 .0001), and a difference persisted, although lessened, throughout the study.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included volumetric BMD at spine and hip by quantitative computed tomography, trabecular bone microarchitecture by magnetic resonance imaging of distal radius, and biochemical bone turnover markers.
Summary · context
Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME.InterventionSubjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 mont…
Report a problemFND-1834906106
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, the P1NP difference between PTH(1-84) and placebo persisted but lessened throughout the study.
In plain wordsIn postmenopausal women, P1NP remained higher with PTH than placebo, but the difference became smaller.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseP1NP during subsequent treatment
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 mug daily for 1 month, then weekly for 11 months · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
After 1 month of daily PTH, N-terminal propeptide of type I collagen (P1NP) was markedly increased compared with placebo (P < 0 .0001), and a difference persisted, although lessened, throughout the study.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included volumetric BMD at spine and hip by quantitative computed tomography, trabecular bone microarchitecture by magnetic resonance imaging of distal radius, and biochemical bone turnover markers.
Summary · context
Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME.InterventionSubjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 mont…
Report a problemFND-1834906107
08HumanNon-randomized trialEfficacy outcome
In postmenopausal women, bone resorption indices were unchanged in PTH(1-84)-treated women and were reduced in the placebo group.
In plain wordsIn postmenopausal women, bone resorption markers were unchanged with PTH and were reduced in the placebo group.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeBone resorption indices
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 mug daily for 1 month, then weekly for 11 months · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Bone resorption indices were unchanged in PTH-treated women and were reduced in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included volumetric BMD at spine and hip by quantitative computed tomography, trabecular bone microarchitecture by magnetic resonance imaging of distal radius, and biochemical bone turnover markers.
Summary · context
Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME.InterventionSubjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 mont…
Report a problemFND-1834906108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.